CrystalGenomics Obtains Australian Patent for Anticancer Drug 'Ivaltinostat'

[Asia Economy Reporter Oh Ju-yeon] CrystalGenomics announced on the 22nd that it has obtained an Australian patent for the new drug candidate 'CG-745 (Ivaltinostat),' which is being developed for indications including pancreatic cancer, liver cancer, and myelodysplastic syndrome (MDS).

This patent is significant in that it maintains exclusive rights to the anticancer drug 'Ivaltinostat' while additionally introducing new salts, greatly improving the stability and productivity of the raw material itself.

Through this, the raw material manufacturing is facilitated, reducing production costs and extending storage periods, which is expected to greatly improve profitability upon future commercialization.

Furthermore, by using the stabilized Ivaltinostat raw material, development into various formulations, including oral formulations that can improve patient compliance in addition to the existing injectable form, has become possible.

The patent title is "Pharmaceutically acceptable salts of alkylcarbamoyl naphthalenyloxy octenoyl hydroxamic acid or its derivatives and their manufacturing methods."

The company stated, "Salt patents filed after the disclosure of the substance patent are mostly determined by the doctrine of selection inventions. Registration of salt patents requires clear description of the effects, and experimental data proving this is most important. Ivaltinostat meets all these conditions."

This patent is valid until April 18, 2038, and will fundamentally prevent other companies from manufacturing using the same salt.

A CrystalGenomics official said, "Starting with Australia, we will actively pursue continuous research and development and strengthen global intellectual property rights with commercialization of the anticancer drug Ivaltinostat in mind."